17607 Gold Plaza, Omaha, NE
402-991-8468
Patient Portal
Menu

News

CMS’ 340B Reform Proposal Is a Good – Long Overdue – First Step

October 11, 2017

The 340B Drug Discount Program is an innocent-sounding program with the best of intentions. But behind it lies a classic tale of government run amok. After 25 years, this critically important safety net for patients in need has been overrun by some “corporate” hospitals that masquerade as nonprofits. While these bad actors make a killing off of 340B, the very patients it was intended to benefit suffer — and all of us taxpayers foot the bill.

View Article

Nivolumab Plus Ipilimumab vs Sunitinib Alone as First- Line Therapy for Metastatic Renal Cell Carcinoma

October 11, 2017

A CHANGE IN PARADIGM may be on the horizon for the treatment of metastatic renal cell carcinoma. According to the results of CheckMate 214, the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) outperformed the standard of care—sunitinib (Sutent)—for first-line treatment, with improved overall response rates, progression-free survival, as well as the gold standard—overall survival in intermediate- and poor-risk patients.

View Article

Multivitamins May Reduce Chemotherapy-Induced Peripheral Neuropathy | Cancer Network | The Oncology Journal

October 10, 2017

Women who take multivitamin supplements before their breast cancer diagnosis and during chemotherapy appear to be less likely to develop the debilitating, often long-lasting symptoms of chemotherapy-induced peripheral neuropathy (CIPN), according to a new study.

View Article

UnitedHealth to Congress: Let cancer patients eat gauze

October 9, 2017

….produce more new cancer treatments as pills so the problem will only get worse. It is estimated that over 60% of the new drugs in the development pipeline are pills and not injection drugs.

View Article

Endocyte Pursuing Phase 3 Trial of 177Lu-PSMA-617 in Prostate Cancer

October 6, 2017

Endocyte announced it will move PSMA-617 quickly into Phase 3 development in prostate cancer after it licensed the compound from German ABX. The trial, for which the company has yet to seek approval, likely will launch by early 2018.

View Article